

•

*

)

(

(**FAA**

HMG-CoA

:

مجله علمی ابن سینا / اداره بهداشت و درمان نهجا (دوره ۹، شماره ۱،
سال ۱۳۸۵، مسلسل ۲۲)

.*

(

)

(

VLDL

)

()

(HMG-CoA

()

()

(

HMG-CoA

(LDL)

HMG-CoA (HDL)

(

HMG-CoA

()

(

LDL

LDL

HMG-CoA

%

%

(

)

.(

(

(

)

aPPAR-

(

aPPAR-

()

(

VLDL

()

LDL

HDL

LDL

VLDL

(

HDL

LDL

VLDL LDL

(

LDL

HDL

(

(NSAID)

(Baycol)

FDA

(HDL, VLDL, LDL)

()

)

(

() HMG-CoA

() FAA

()

FAA :

(Lopid)

(Mevacor)

(Pravachol)

(Questran)

(Zocor)

(Lipitor)

(Crestor)

(Zetia)

1. Katzung G. Pharmacology: Examination and board review. McGraw Hill, 7th ed; 2005.
2. MEDICATIONS AND AIRCREW, Available from: <http://www.dciem.dnd.ca/medical/meds-e.html>.
3. Medication Information, January 8, 2005, Available from: <http://www.aviationmedicine.com/meds.htm>.

Anti hyperlipidemia drugs and flight

Abstract

Nowadays one of the most important reasons of death is Atherosclerosis. Drug therapy in hyperlipidemia prevents from Atherosclerosis side effects (such as cardiac attack, peripheral arterial diseases & strokes) and reduces mortality in patients with past history of hyperlipidemia and cardiovascular diseases.

FAA (In civil part) permits aircrew to use some of these medications if there is not any side effects as Health Canadian Air Force Guidelines (In military part), pharmacological treatment for hyperlipidemia should be initiated only after a reasonable trial of diet and life-style modification and if required treatment with an HMG-CoA reductase inhibitor is recommended.

In hypertriglyceridemia the use of a fibrate maybe indicated.

Aircrew should be grounded for the first two weeks during the initiation of drug therapy for hyperlipidemia and require bimonthly monitoring of lipid & transaminase levels during the first six months of treatment and can use these drugs during flight if there are not any side effects.

Keywords: Atherosclerosis, Hyperlipidemia, Flight

Ghazizadeh K, M.D.

IRIAF Health Administration